The p53/p21Cip1/ Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression
暂无分享,去创建一个
J. Ortonne | R. Ballotti | G. Robert | M. Deckert | S. Rocchi | S. Tartare-Deckert | A. Puissant | M. Dufies | N. Fenouille | M. Tichet | Nina Fenouille
[1] D. Dinh,et al. Cathepsin B facilitates autophagy-mediated apoptosis in SPARC overexpressed primitive neuroectodermal tumor cells , 2010, Cell Death and Differentiation.
[2] T. Nakatsura,et al. Silencing of secreted protein acidic and rich in cysteine inhibits the growth of human melanoma cells with G1 arrest induction , 2010, Cancer science.
[3] P. Fortina,et al. p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo , 2009, Proceedings of the National Academy of Sciences.
[4] H. Frierson,et al. The role of SPARC in the TRAMP model of prostate carcinogenesis and progression , 2009, Oncogene.
[5] Anindya Dutta,et al. p21 in cancer: intricate networks and multiple activities , 2009, Nature Reviews Cancer.
[6] P. Abbe,et al. Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest. , 2009, Cancer research.
[7] M. Colombo,et al. Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. , 2008, Cancer research.
[8] M. Colombo,et al. Matricellular proteins at the crossroad of inflammation and cancer. , 2008, Cancer letters.
[9] A. Mauviel,et al. JNK supports survival in melanoma cells by controlling cell cycle arrest and apoptosis , 2008, Pigment cell & melanoma research.
[10] E. Sage,et al. A prototypic matricellular protein in the tumor microenvironment—Where there's SPARC, there's fire , 2008, Journal of cellular biochemistry.
[11] Eduardo Sontag,et al. Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.
[12] James M. Roberts,et al. CDK Inhibitors : Cell Cycle Regulators and Beyond , 2008 .
[13] B. Gardiner,et al. Osteonectin downregulates E‐cadherin, induces Osteopontin and Focal adhesion kinase activity stimulating an invasive melanoma phenotype , 2007, International journal of cancer.
[14] M. Tang,et al. A Novel Interaction between Procaspase 8 and SPARC Enhances Apoptosis and Potentiates Chemotherapy Sensitivity in Colorectal Cancers* , 2007, Journal of Biological Chemistry.
[15] O. Podhajcer,et al. SPARC endogenous level, rather than fibroblast-produced SPARC or stroma reorganization induced by SPARC, is responsible for melanoma cell growth. , 2007, The Journal of investigative dermatology.
[16] N. Said,et al. Normalization of the Ovarian Cancer Microenvironment by SPARC , 2007, Molecular Cancer Research.
[17] D. Bigner,et al. Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases , 2007, Oncogene.
[18] A. Sánchez-Aguilera,et al. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. , 2007, Cancer research.
[19] Carlos Cordon-Cardo,et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.
[20] C. Iacobuzio-Donahue,et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Jane Goodall,et al. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. , 2006, Genes & development.
[22] P. Abbe,et al. SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. , 2006, Cancer research.
[23] T. Golub,et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.
[24] Mariano J. Alvarez,et al. Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity. , 2005, Cancer research.
[25] M. Herlyn,et al. Adhesion, migration and communication in melanocytes and melanoma. , 2005, Pigment cell research.
[26] P. Abbe,et al. HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1 , 2005, Oncogene.
[27] L. Larue,et al. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression , 2005, Nature.
[28] D. Bigner,et al. Secreted Protein Acidic, Rich in Cysteine (SPARC), Mediates Cellular Survival of Gliomas through AKT Activation* , 2004, Journal of Biological Chemistry.
[29] E Helene Sage,et al. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. , 2004, Molecular cancer research : MCR.
[30] M. Colombo,et al. Leukocyte, Rather than Tumor-produced SPARC, Determines Stroma and Collagen Type IV Deposition in Mammary Carcinoma , 2003, The Journal of experimental medicine.
[31] E Helene Sage,et al. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. , 2003, Cancer research.
[32] J. Piette,et al. Permanent cell cycle exit in G2 phase after DNA damage in normal human fibroblasts , 2003, The EMBO journal.
[33] R. Brekken,et al. Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. , 2003, The Journal of clinical investigation.
[34] O. Volpert,et al. SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. , 2002, Cancer research.
[35] P. Bornstein,et al. Matricellular proteins: extracellular modulators of cell function. , 2002, Current opinion in cell biology.
[36] R. Berkowitz,et al. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. , 2001, The American journal of pathology.
[37] E. Sage,et al. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. , 2001, The Journal of clinical investigation.
[38] G. Stark,et al. Regulation of the G2/M transition by p53 , 2001, Oncogene.
[39] G. Stark,et al. p130/E2F4 Binds to and Represses the cdc2 Promoter in Response to p53* , 2001, The Journal of Biological Chemistry.
[40] R. Medema,et al. p21 Inhibits Thr161 Phosphorylation of Cdc2 to Enforce the G2 DNA Damage Checkpoint* , 2000, The Journal of Biological Chemistry.
[41] J. Pietenpol,et al. p53 Regulation of G2 Checkpoint Is Retinoblastoma Protein Dependent , 2000, Molecular and Cellular Biology.
[42] S. Jackson,et al. Regulation of p53 in response to DNA damage , 1999, Oncogene.
[43] D. Massi,et al. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. , 1999, Human pathology.
[44] K. Kinzler,et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.
[45] J N Weinstein,et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.
[46] O. Podhajcer,et al. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells , 1997, Nature Medicine.
[47] Stephen J. Elledge,et al. Cell Cycle Checkpoints: Preventing an Identity Crisis , 1996, Science.
[48] N. Hayward,et al. Mutation and expression of the p53 gene in human malignant melanoma , 1994, Melanoma research.
[49] David Beach,et al. p21 is a universal inhibitor of cyclin kinases , 1993, Nature.
[50] J. Trent,et al. WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.
[51] W. Cavenee,et al. Mutation and expression of the p53 gene in malignant melanoma cell lines , 1993, International journal of cancer.
[52] P. Higgins,et al. Modulation of SPARC expression during butyrate-induced terminal differentiation of cultured human keratinocytes: regulation via a TGF-beta-dependent pathway. , 1993, Experimental cell research.
[53] Andrea S. Llera,et al. The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host , 2008, Cancer and Metastasis Reviews.
[54] M. Herlyn,et al. Osteonectin/SPARC induction by ectopic beta(3) integrin in human radial growth phase primary melanoma cells. , 2002, Cancer research.
[55] R. Brekken,et al. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. , 2001, Matrix biology : journal of the International Society for Matrix Biology.